World Health Organization‐defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management

@article{Gotlib2015WorldHO,
  title={World Health Organization‐defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management},
  author={Jason Gotlib},
  journal={American Journal of Hematology},
  year={2015},
  volume={90}
}
  • J. Gotlib
  • Published 1 November 2015
  • Medicine
  • American Journal of Hematology
Disease overview: The eosinophilias encompass a broad range of non‐hematologic (secondary or reactive) and hematologic (primary, clonal) disorders with potential for end‐organ damage. 
IgG4‐related disease and lymphocyte‐variant hypereosinophilic syndrome: A comparative case series
To compare the clinical and laboratory features of IgG4‐related disease (IgG4‐RD) and lymphocyte‐variant hypereosinophilic syndrome (L‐HES), two rare diseases that often present with lymphadenopathy,Expand
HOW I DIAGNOSE HYPEREOSINOPHILIC SYNDROMES *
Hypereosinophilic syndromes are a group of disorders characterised by significant eosinophilia and organ damage. They have proven challenging to define, diagnose, and study for many years, due inExpand
The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes
Fusion genes derived from the platelet-derived growth factor receptor beta (PDGFRB) or alpha (PDGFRA) play an important role in the pathogenesis of eosinophilia-associated myeloproliferative neopla...
Eosinophilic Diseases : A Spotlight
1,8,9 organ dysfunction attributable to the eosinophilia. Eosinophil-associated diseases (EADs) are a group of disorders with multisystem manifestations, where eosinophils play a primary role. TheseExpand
A 68-year old woman with asymptomatic hypereosinophilia.
TLDR
This work presents the case of a 68-year-old woman with isolated asymptomatic hypereosinophilia, a group of heterogeneous disorders with persistent eos inophilia and organ involvement. Expand
NON-CLASSIC MYELOPROLIFERATIVE NEOPLASMS : ARE WE REALLY AWARE OF THESE RARE DISEASES IN DAILY PRACTICE ? *
Chronic neutrophilic leukaemia (CNL), chronic eosinophilic leukaemia-not otherwise specified (CEL-NOS), and myeloproliferative neoplasm (MPN), unclassifiable are rare clonal diseases, known asExpand
Myeloid/Lymphoid neoplasms with abnormalities of PDGFRA
This insert represents a review of myeloid and lymphoid neoplasms with abnormalities of PDGFRA including clinical presentation, morphologic review, and cytogenetic findings.
Updates for the treatment of EGPA.
TLDR
The rationale underlying the routine treatment strategy, which relies mainly on corticosteroids, with immunosuppressant adjunction for severe disease is highlighted and clinical data on new treatment options are discussed and therapeutic strategies are proposed. Expand
Hypereosinophilic Syndrome After Liver Transplantation: A Case Report and a Review of the Literature
TLDR
A 12-year-old boy who developed severe hypereosinophilia 11 years after liver transplantation due to biliary atresia was reported, and treatment with prednisolone resulted in an immediate response with rapid reduction of eos inophils, normalization of liver enzymes, and amelioration of any clinical symptoms. Expand
Idiopathic hypereosinophilic syndrome presenting with hepatitis and achalasia
TLDR
This is the first report of a patient presenting with hepatitis and achalasia related to idiopathic HES, and it is estimated that gastrointestinal or liver involvement is estimated to affect up to one-third of patients with HES. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 200 REFERENCES
Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes
TLDR
Little is known about the impact of eosinophils and basophils in patients with myelodysplastic syndromes, but the prognostic value of neutropenia, thrombocytopenia and monocytosis have been documented. Expand
THE HYPEREOSINOPHILIC SYNDROME: Analysis of Fourteen Cases With Review of The Literature
TLDR
A group of 14 patients had hematologic, cardiac, and neurologic abnormalities attributable to this disease, and patient survival and response to chemotherapy was significantly better in this group than in previously reported patients. Expand
Eosinophilia: secondary, clonal and idiopathic
TLDR
The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment. Expand
Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation.
A patient with well-documented hypereosinophilic syndrome who underwent successful allogeneic bone marrow transplantation (BMT) is reported. This therapeutic modality should be considered in patientsExpand
Carbamazepine‐induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: report of four cases and brief review
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare but severe drug reaction, most commonly to aromatic anticonvulsants with a delayed onset, variable clinicalExpand
Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation.
A patient with well-documented hypereosinophilic syndrome who underwent successful allogeneic bone marrow transplantation (BMT) is reported. This therapeutic modality should be considered in patientsExpand
Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations
TLDR
Dr. Roufosse provides an updated classification of hypereosinophilic syndromes and discusses the recent advances in this field, including fascinating pathogenic mechanisms and novel targeted therapeutic approaches. Expand
Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript
Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript
Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome
Long-term follow-up of FIP1L1-PDGFRA -mutated patients with eosinophilia: survival and clinical outcome
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia
Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia
...
1
2
3
4
5
...